Tetramethylthiuram monosulfide
Based on 1 Customer Validation
Tetramethylthiuram monosulfide (TMTM) is an orally active microsomal monooxygenases inhibitor. Tetramethylthiuram monosulfide is used as an accelerator and activator in the processing of natural rubber and butyl rubber. Tetramethylthiuram monosulfide reduces palmitic acid incorporation into microsomal phospholipids, disrupts microsomal membrane integrity, and impairs electron transport during oxygenation. Tetramethylthiuram monosulfide can be used for the research of fungal infection, bacterial infection and allergic contact dermatitis.
For research use only. We do not sell to patients.
- Purity: 99.71%
- CAS No.: 97-74-5
- Formula: C6H12N2S3
- Molecular Weight:208.37
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Bioactive Compound Library Max
HY-L181
-
Bioactive Compound Library
HY-L001
-
Anti-Infection Compound Library
HY-L002
-
Immunology/Inflammation Compound Library
HY-L007
-
Metabolism/Protease Compound Library
HY-L012
-
Antibacterial Compound Library
HY-L049
-
Orally Active Compound Library
HY-L061
-
MCE Bioactive Compound Library
HY-L001V
-
Structurally Diverse Fragment Library
HY-L187
-
High-Throughput Bioactive Compound Library
HY-L205
Biological Activity
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HeLa | IC50 |
>5000 μM
Compound: 9
|
Cytotoxicity against human HeLa cells after 24 hrs by MTT assay
Cytotoxicity against human HeLa cells after 24 hrs by MTT assay
|
[PMID: 29216562] |
Tetramethylthiuram monosulfide (10-2000 μg/plate; 48 h) induces point mutations in Salmonella typhimurium LT2 strains TA 100 and TA 1535 (especially with metabolic activation) and has a weak mutagenic effect in strain TA 1537, but does not induce mutations in strains TA 98 and TA 1538; higher doses exhibit bacteriotoxicity[1].
Tetramethylthiuram monosulfide (0.2 ppm; 96 h) is cytotoxic to normal Hartley guinea pig lymph node cells at concentrations of 0.2 ppm and above when incubated with PHA stimulation[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Tetramethylthiuram monosulfide (500-2500 mg/kg; p.o.; single dose) has an acute oral LD50 of 818 mg/kg in adult female NMRI mice, with dose-dependent mortality and characteristic intoxication symptoms[1].
Tetramethylthiuram monosulfide (5%; intradermal injection; epicutaneous via occlusive patch for sensitization; 2.0%; epicutaneous via Finn chamber, 24 hours for challenge) induces contact hypersensitivity in female Hartley guinea pigs, with 62.5% of sensitized animals displaying positive patch test reactions after epicutaneous challenge[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Wistar (adult female, SPF, 180-200 g)[1]
-
Dosage:26 mg/kg; 867 mg/kg
-
Administration:p.o.; single dose or 5 consecutive days per week for 4 weeks
-
Result:Prolonged hexobarbital sleeping time significantly, and decreased incorporation of [1-14C] palmitic acid into microsomal phospholipids of isolated perfused livers (26 mg/kg single dose).
Left zoxazolamine paralysis time unchanged (26 mg/kg single dose).
Prolonged both hexobarbital sleeping time and zoxazolamine paralysis time significantly, and produced a greater decrease in [1-14C] palmitic acid incorporation into all microsomal phospholipids compared to the 26 mg/kg dose (867 mg/kg single dose).
Decreased erythrocyte count from 5.96×106 to 4.32×106 significantly (26 mg/kg/day, 4-week treatment).
Decreased hemoglobin content from 14.19 g% to 13.20 g% significantly (26 mg/kg/day, 4-week treatment).
Caused initial body weight loss with moderate ongoing reduction, decreased food intake, increased water consumption, increased relative liver weight, and mild histopathological changes including generalized hepatocellular swelling and renal tubular epithelial swelling (26 mg/kg/day, 4-week treatment).
Left blood clinicochemical parameters (total protein, BUN, creatinine, alkaline phosphatase, GPT) and hepatic microsomal parameters (protein, cytochrome P-450, glucose-6-phosphatase, malondialdehyde, O-demethylase activity) unchanged (26 mg/kg/day, 4-week treatment).
-
Animal Model:NMRI (adult female, 20-25 g, acute toxicity)[1]
-
Dosage:500 mg/kg; 750 mg/kg; 1000 mg/kg; 1250 mg/kg; 1500 mg/kg; 2000 mg/kg; 2250 mg/kg; 2500 mg/kg
-
Administration:p.o.; single dose
-
Result:Resulted in an acute oral LD50 of 818 mg/kg.
Caused intoxication symptoms including tachypnea, tachycardia, miosis, rare convulsions, and extremity paralysis.
Showed dose-dependent mortality onset, varying from 1 hour (2500 mg/kg) to 24 hours across doses.
-
Animal Model:Hartley (female, 300-400 g)[3]
-
Dosage:5% (sensitization); 2.0% (challenge)
-
Administration:intradermal injection; epicutaneous via occlusive patch (sensitization); epicutaneous via Finn chamber, 24 hours (challenge)
-
Result:Induced positive patch test reactions in 62.5% of sensitized guinea pigs.
Induced doubtful reactions in 25% of sensitized guinea pigs.
Induced negative reactions in 12.5% of sensitized guinea pigs.
Resulted in negative reactions in all control guinea pigs.
Chemical Information
-
CAS No. 97-74-5
-
Appearance Solid
-
Molecular Weight 208.37
-
Formula C6H12N2S3
-
Color Light yellow to yellow
-
SMILES
S=C(SC(N(C)C)=S)N(C)C
-
Synonyms
TMTM
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Solvent & Solubility
DMSO : 200 mg/mL (959.83 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (9.98 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (9.98 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (276 KB)
-
SDS (597 KB)
- English - EN (597 KB)
- Français - FR (597 KB)
- Deutsch - DE (597 KB)
- Norwegian - NO (597 KB)
- Español - ES (597 KB)
- Swedish - SV (597 KB)
- Italian - IT (597 KB)
- Korean - KR (597 KB)
- Portuguese - PT (597 KB)
-
Handling Instructions (2659 KB)
References
[1]. Alanis OT, et al. Toxicity studies on tetramethylthiuram monosulfide. Environ Res. 1982 Jun;28(1):199-211. [Content Brief]
[2]. Li Q, et al. Evaluation of contact sensitivity to formaldehyde and tetramethylthiuram monosulfide using a modified lymphocyte transformation test. Toxicology. 1995;104(1-3):17-23. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 4.7992 mL | 23.9958 mL | 47.9916 mL | 119.9789 mL |
| 5 mM | 0.9598 mL | 4.7992 mL | 9.5983 mL | 23.9958 mL | |
| 10 mM | 0.4799 mL | 2.3996 mL | 4.7992 mL | 11.9979 mL | |
| 15 mM | 0.3199 mL | 1.5997 mL | 3.1994 mL | 7.9986 mL | |
| 20 mM | 0.2400 mL | 1.1998 mL | 2.3996 mL | 5.9989 mL | |
| 25 mM | 0.1920 mL | 0.9598 mL | 1.9197 mL | 4.7992 mL | |
| 30 mM | 0.1600 mL | 0.7999 mL | 1.5997 mL | 3.9993 mL | |
| 40 mM | 0.1200 mL | 0.5999 mL | 1.1998 mL | 2.9995 mL | |
| 50 mM | 0.0960 mL | 0.4799 mL | 0.9598 mL | 2.3996 mL | |
| 60 mM | 0.0800 mL | 0.3999 mL | 0.7999 mL | 1.9996 mL | |
| 80 mM | 0.0600 mL | 0.2999 mL | 0.5999 mL | 1.4997 mL | |
| 100 mM | 0.0480 mL | 0.2400 mL | 0.4799 mL | 1.1998 mL |
Tetramethylthiuram monosulfide Related Classifications
HY-W020246 Related Classifications
Powered by Bioz
- Tetramethylthiuram monosulfide
- 97-74-5
- TMTM
- Squalene Monooxygenase
- Bacterial
- microsomal aliphatic hydroxylase
- succinic dehydrogenase
- cytochrome oxidase
- Salmonella typhimurium LT2 strains TA 100
- microsomal phospholipids
- female NMRI mice
- palmitic acid
- allergic contact dermatitis
- Hartley guinea pig lymph node cells
- Salmonella typhimurium LT2 strains TA 1535
- Inhibitor
- inhibitor
- inhibit